Notice2024-05878
Prospective Grant of an Exclusive Patent License: Manufacturing of Anti-Malaria Monoclonal Antibody L9LS in Transgenic Cows and Sheep
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
March 20, 2024
Issuing agencies
Health and Human Services DepartmentNational Institutes of Health
Abstract
The National Institute of Allergy and Infectious Diseases, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an Exclusive Patent License to practice inventions embodied in the Patents and Patent Applications listed in the Supplementary Information section of this Notice to Taurgen Malaria, Inc. ("Taurgen"), headquartered in Logan, UT. Taurgen Malaria, Inc. is a wholly-owned subsidiary of Taurgen Therapeutics, LLC, which is also headquartered in Logan, UT.
Full Text
<html>
<head>
<title>Federal Register, Volume 89 Issue 55 (Wednesday, March 20, 2024)</title>
</head>
<body><pre>
[Federal Register Volume 89, Number 55 (Wednesday, March 20, 2024)]
[Notices]
[Pages 19855-19856]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2024-05878]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Prospective Grant of an Exclusive Patent License: Manufacturing
of Anti-Malaria Monoclonal Antibody L9LS in Transgenic Cows and Sheep
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The National Institute of Allergy and Infectious Diseases, an
institute of the National Institutes of Health, Department of Health
and Human Services, is contemplating the grant of an Exclusive Patent
License to practice inventions embodied in the Patents and Patent
Applications listed in the Supplementary Information section of this
Notice to Taurgen Malaria, Inc. (``Taurgen''), headquartered in Logan,
UT. Taurgen Malaria, Inc. is a wholly-owned subsidiary of Taurgen
Therapeutics, LLC, which is also headquartered in Logan, UT.
[[Page 19856]]
DATES: Only written comments and/or applications for a license which
are received by the National Institute of Allergy and Infectious
Diseases' Technology Transfer and Intellectual Property Office on or
before April 4, 2024 will be considered.
ADDRESSES: Requests for copies of the patent applications, inquiries,
and comments relating to the contemplated Exclusive Patent License
should be directed to: Wade Green, Ph.D., Lead Technology Transfer and
Patent Specialist, Technology Transfer and Intellectual Property
Office, National Institute of Allergy and Infectious Diseases
Telephone: (301) 761-7505; Email: <a href="/cdn-cgi/l/email-protection#9fe8fefbfab1f8edfafaf1dff1f6f7b1f8f0e9"><span class="__cf_email__" data-cfemail="cabdabaeafe4adb8afafa48aa4a3a2e4ada5bc">[email protected]</span></a>.
SUPPLEMENTARY INFORMATION:
Intellectual Property
1. United States Provisional Patent Application No. 62/842,590,
filed May 03, 2019, titled ``Neutralizing antibodies to Plasmodium
falciparum circumsporozoite protein and their use'' [HHS Reference No.
E-087-2019-0-US-01];
2. International Patent Application No. PCT/US2020/031345, filed
May 04, 2020, titled ``Neutralizing antibodies to Plasmodium falciparum
circumsporozoite protein and their use'' [HHS Reference No. E-087-2019-
0-PCT-01];
3. European Patent Application No. 20727798.9, filed May 04, 2020,
titled ``Neutralizing antibodies to Plasmodium falciparum
circumsporozoite protein and their use'' [HHS Reference No. E-087-2019-
0-EP-02]; and
4. United States Patent Application No. 17/608,381, filed October
02, 2021, titled ``Neutralizing antibodies to Plasmodium falciparum
circumsporozoite protein and their use'' [HHS Reference No. E-087-2019-
0-US-03].
The patent rights in these inventions have been assigned and/or
exclusively licensed to the government of the United States of America.
The prospective exclusive license territory may be worldwide, and
the field of use may be limited to the following:
``Production of the L9LS monoclonal antibody in transgenic bovine
and ovine species.''
The E-087-20219 patent family is primarily directed to (1)
compositions of matter of the L9LS monoclonal antibody, (2) methods of
treating and preventing infection with Plasmodium falciparum using the
L9LS monoclonal antibody, and (3) methods of manufacturing the L9LS
monoclonal antibody. The exclusive field of use which may be granted to
Taurgen applies to only manufacturing of the L9LS monoclonal antibody
in transgenic bovine and ovine species. Accordingly, the proposed scope
of rights which may be conveyed under the license covers only a portion
of total scope of the E-087-2019 patent family and only a subset of the
possible methods of manufacturing the L9LS monoclonal antibody.
This Notice is made in accordance with 35 U.S.C. 209 and 37 CFR
part 404. The prospective exclusive license will be royalty bearing,
and the prospective exclusive license may be granted unless within
fifteen (15) days from the date of this published Notice, the National
Institute of Allergy and Infectious Diseases receives written evidence
and argument that establishes that the grant of the license would not
be consistent with the requirements of 35 U.S.C. 209 and 37 CFR part
404.
In response to this Notice, the public may file comments or
objections. Comments and objections, other than those in the form of a
license application, will not be treated confidentially and may be made
publicly available.
Complete license applications submitted in response to this Notice
will be presumed to contain business confidential information and any
release of information from these license applications will be made
only as required and upon a request under the Freedom of Information
Act, 5 U.S.C. 552.
Dated: March 14, 2024.
Surekha Vathyam,
Acting Director, Technology Transfer and Intellectual Property Office,
National Institute of Allergy and Infectious Diseases.
[FR Doc. 2024-05878 Filed 3-19-24; 8:45 am]
BILLING CODE 4140-01-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>Indexed from Federal Register on March 20, 2024.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.